Safety PK and Antiviral Activity of PGT121 Monoclonal Antibody in HIV-uninfected and HIV-infected Adults
This is a Phase 1 study to evaluate the safety, tolerability, pharmacokinetics and anti-viral efficacy of the PGT121 monoclonal antibody for HIV prevention and therapy.
A Phase 1 Randomized Placebo-controlled Clinical Trial of the Safety, Pharmacokinetics and Antiviral Activity of PGT 121 Monoclonal Antibody (mAb) in HIV-uninfected and HIV-infected Adults
- ClinicalTrials.gov Identifier: NCT02960581
- Protocol Number: 2016P000301
- Principal Investigator: Kathryn Stephenson
Contact the research team to learn more about this study.
Fields marked with asterisk (*) are required